盐酸羟考酮缓释片联合阿米替林治疗重度癌症疼痛的临床研究

Clinical trial of oxycodone hydrochloride sustained-release tablets combined with amitriptyline in the treatment of severe cancer pain

目的观察盐酸羟考酮缓释片联合阿米替林对重度癌症疼痛缓解的影响。方法回顾性分析重度癌症疼痛患者的病历资料,试验组30例,对照组30例。对照组给予盐酸羟考酮缓释片,每12 h 10 mg,据患者病情加量;试验组在对照组的基础上给予阿米替林12.5 mg,每天1次,据患者症状情况可逐渐加量至25 mg。治疗前和治疗后2,4周,分别观察患者的面部表情疼痛量表(FPS-R)评分,治疗后4周监测患者疼痛缓解情况,并记录治疗过程中的药物不良反应。结果治疗后2周,对照组与试验组FPS-R评分分别为(4.01±0.84),(3.11±0.61)分;治疗后4周分别为(3.20±0.59),(2.65±0.57)分,差异有统计学意义(P<0.05)试验组和对照组的总缓解率分别为73.3%,56.7%,差异有统计学意义(P<0.05)。2组药物不良反应发生率差异无统计学意义(P>0.05)。结论盐酸羟考酮缓释片联合阿米替林治疗重度癌症疼痛,有利于患者症状的缓解,且能有效改善患者生活质量。

Objective To explore the effect of oxycodone hydrochloride sustained-release tablets combined with amitriptyline on pain relief in patients with severe cancer pain.Methods Retrospective analysis of medical records of patients with severe cancer pain,30 patients in treatment group and 30 patients in control group.Control group was treated with oxycodone hydrochloride sustained-release tablets,every 12 h 10 mg,increasing the dose according to the illness of patients.Treatment group was treated with oxycodone hydrochloride sustained-release tablets combined with amitriptyline 12.5 mg per time,1 time per day,increasing the dose to 25 mg gradually according to the symptoms of patients.The patients’faces pain scale-revised(FPS-R)scores were observed before treatment and 2,4 weeks after treatment,and the pain relief were monitored 4 weeks after treatment,and the adverse drug reactions during the treatment were recorded.Results The FPS-R pain score in control group and treatment group at 2 weeks after treatment were 4.01±0.84,3.11±0.61;at 4 weeks after treatment were 3.20±0.59,2.65±0.57,with significant difference(P<0.05).The total response rate in treatment group and control group were 73.3%,56.7%,with significant difference(P<0.05).There was no significant difference in the incidence of adverse drug reactions between the two groups(P>0.05).Conclusion For patients with severe cancer pain,the treatment with oxycodone hydrochloride sustained-release tablets combined with amitriptyline is more conducive to the relief of symptoms,can effectively improve the quality of life of patients.